Валеология: Здоровье, Болезнь, Выздоровление. 2019; : 45-47
ОСТРЫЙ КОРОНАРНЫЙ СИНДРОМ У ПОТРЕБИТЕЛЕЙ ПСИХОАКТИВНЫХ ВЕЩЕСТВ
Аннотация
Учитывая широкую распространенность и доступность психоактивных веществ (ПАВ), в настоящее время практикующие врачи столкнулись с новыми разновидностями психотических нарушений и полным отсутствием стандартов и протоколов ведения таких пациентов. На сегодняшний день лечение огромного спектра нарушений, связанных с употреблением ПАВ, остается симптоматическим. Знание особенностей течения и подходов в диагностике и оказании квалифицированной помощи при ОКС у потребителей ПАВ позволит избежать серьезных ятрогенных осложнений.
Список литературы
1. International Narcotics Control Board (Международный комитет по контролю над наркотиками). Официальный сайт. - URL: http://www.incb.org./.
2. EMCDDA, European Monitoring Centre for Drugs and Drug Addiction European Drug Report 2014: Trends and developments. Luxembourg: Publications Office of the. – 2014. – P. 8–79.
3. Nobis F. “Legal-High”- Produkte – wirklich illegal? Oder: wie ein Aufsatz sich verselbstständigt. NStZ . - 2012; 422.
4. Europäische Beobachtungsstelle für Drogen und Drogensucht. Europäischer Drogenbericht. Trends und Entwicklungen. Luxemburg: Amt für Veröffentlichungen der Europäischen Union, 2013. URL: http://www.emcdda.europa.eu/attachements.cfm/att_213154_DE_TDAT13001DEN1.pdf.
5. Cottencin, O., Rolland, B., Karila, L., New designer drugs (synthetic cannabinoids and synthetic cathinones): reviewof literature // J. Curr Pharm Des. 2014. – Vol. 20. – P. 4106–11.
6. McKetin R, Lubman D. I., Baker A. L., Dawe S., Ali R. L. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA Psychiatry. 2013; 70 : 319–324. doi:10.1001/jamapsychiatry.2013.283
7. Wearne T. A., Cornish J. L. A comparison of methamphetamine-induced psychosis and schizophrenia: a review of positive, negative, and cognitive symptomatology. Front Psychiatry. 2018; 9 : 491. doi: 10.3389/fpsyt.2018.00491
8. Fattore L., Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 2011; 5 : 60, https://doi.org/10.3389/fnbeh.2011.00060.
9. Ларченко А. В. Cинтетические катиноны и каннабиоиды - новые психоактивные вещества (обзор) / А. В. Ларченко [и др.] – СТМ. – 2017 - Т. 9, № 1. - С. 185-197.
10. Rosenbaum, C. D., Carreiro, S. P., Babu, K. M., Here today, gone tomorrow...and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines // J Med Toxicol. – 2012. – Vol. 8. – P. 15–32.
11. Winstock A. R., Mitcheson L. R., Deluca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop? Addiction 2011; 106 (1) : 154–161, https://doi.org/10.1111/j.1360-0443.2010.03130.x.
12. Dargan P., Wood D. Technical report on mephedrone. In: EMCDDA. Risk assessments. Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances. Lisbon; 2011; p. 49–102.
13. Гипертонические кризы / под ред. Терещенко С. Н., Плавунова Н. Ф. - 2-е изд. - Москва. - "МЕДпресс-информ", 2013. - 208 с.
14. Darke S., Duflou J., Kaye S. Prevalence and nature of cardiovascular disease in methamphetamine-related death: a national study. Drug Alcohol Depend. 2017; 179 : 174–179. doi: 10.1016/j.drugalcdep.2017.07.001
15. Kaye S., Darke S., Duflou J., McKetin R. Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Addiction. 2008; 103 : 1353–1360. doi: 10.1111/j.1360-0443.2008.02231.x
Valeology: Health - Illnes - recovery. 2019; : 45-47
ACUTE CORONARY SYNDROME IN PSYCHOACTIVE SURFACTANT USERS
Abstract
Taking into consideration the wide prevalence and availability of psychoactive substances (PS), currently, practitioners are faced with new varieties of psychotic disorders and a complete lack of standards and guidelines of such patients` management. Presently, the treatment of a huge spectrum of disorders associated with the usage of psychoactive substances, remains symptomatic. Knowledge of the peculiarities of the course and approaches in the diagnostics and providing of qualified care for ACS in psychoactive surfactant users will allow to avoid serious iatrogenic complications.
References
1. International Narcotics Control Board (Mezhdunarodnyi komitet po kontrolyu nad narkotikami). Ofitsial'nyi sait. - URL: http://www.incb.org./.
2. EMCDDA, European Monitoring Centre for Drugs and Drug Addiction European Drug Report 2014: Trends and developments. Luxembourg: Publications Office of the. – 2014. – P. 8–79.
3. Nobis F. “Legal-High”- Produkte – wirklich illegal? Oder: wie ein Aufsatz sich verselbstständigt. NStZ . - 2012; 422.
4. Europäische Beobachtungsstelle für Drogen und Drogensucht. Europäischer Drogenbericht. Trends und Entwicklungen. Luxemburg: Amt für Veröffentlichungen der Europäischen Union, 2013. URL: http://www.emcdda.europa.eu/attachements.cfm/att_213154_DE_TDAT13001DEN1.pdf.
5. Cottencin, O., Rolland, B., Karila, L., New designer drugs (synthetic cannabinoids and synthetic cathinones): reviewof literature // J. Curr Pharm Des. 2014. – Vol. 20. – P. 4106–11.
6. McKetin R, Lubman D. I., Baker A. L., Dawe S., Ali R. L. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA Psychiatry. 2013; 70 : 319–324. doi:10.1001/jamapsychiatry.2013.283
7. Wearne T. A., Cornish J. L. A comparison of methamphetamine-induced psychosis and schizophrenia: a review of positive, negative, and cognitive symptomatology. Front Psychiatry. 2018; 9 : 491. doi: 10.3389/fpsyt.2018.00491
8. Fattore L., Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 2011; 5 : 60, https://doi.org/10.3389/fnbeh.2011.00060.
9. Larchenko A. V. Cinteticheskie katinony i kannabioidy - novye psikhoaktivnye veshchestva (obzor) / A. V. Larchenko [i dr.] – STM. – 2017 - T. 9, № 1. - S. 185-197.
10. Rosenbaum, C. D., Carreiro, S. P., Babu, K. M., Here today, gone tomorrow...and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines // J Med Toxicol. – 2012. – Vol. 8. – P. 15–32.
11. Winstock A. R., Mitcheson L. R., Deluca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop? Addiction 2011; 106 (1) : 154–161, https://doi.org/10.1111/j.1360-0443.2010.03130.x.
12. Dargan P., Wood D. Technical report on mephedrone. In: EMCDDA. Risk assessments. Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances. Lisbon; 2011; p. 49–102.
13. Gipertonicheskie krizy / pod red. Tereshchenko S. N., Plavunova N. F. - 2-e izd. - Moskva. - "MEDpress-inform", 2013. - 208 s.
14. Darke S., Duflou J., Kaye S. Prevalence and nature of cardiovascular disease in methamphetamine-related death: a national study. Drug Alcohol Depend. 2017; 179 : 174–179. doi: 10.1016/j.drugalcdep.2017.07.001
15. Kaye S., Darke S., Duflou J., McKetin R. Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Addiction. 2008; 103 : 1353–1360. doi: 10.1111/j.1360-0443.2008.02231.x
